Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

OS SoC for 1st-line and Relapsed/refractory patients was 16.2 months for 1st-line patients and 12.5m for R/R payients per this IASCL 2019 abstract

P2.01-103 - Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
10:15 - 10:15 | Presenting Author(s): Sai-Hong I Ou | Author(s): Maral Dersarkissian, Rachel Bhak, Huamao M Lin, Shuanglian Li, Mu Cheng, Angie Lax, Hui Huang, Mei Sheng Duh
? Abstract
Background
Mutations in the epidermal growth factor receptor (EGFR) gene have been identified in 10-50% of patients with non-small cell lung cancer (NSCLC), and 2-10% are exon 20 insertion mutations. This study describes real-world characteristics, treatment patterns, and overall survival (OS) of NSCLC patients with EGFR exon 20 insertions.
Method
Flatiron Health electronic health record data from 1/2011-4/2018 were used for this retrospective study. Treatment-naïve (TN) and relapsed/refractory (RR) patients with advanced/metastatic NSCLC with EGFR exon 20 insertion mutation aged ≥18 years at treatment initiation were included. Patient characteristics were described, and Kaplan-Meier analyses were used to assess OS for TN and RR patients.
Result
There were 128 TN and 71 RR patients identified. Median age was 66.5 and 65.0 years for TN and RR patients, respectively, and over half were female (TN: 59.4%, RR: 53.5%). Among 83 TN and 47 RR patients with known ECOG score at advanced diagnosis, most had score 0-1 (TN: 56.3%, RR: 62.0%). Central nervous system metastases were observed in 35.2% of TN and 33.8% of RR patients. 45.3% of TN patients and 23.9% of RR patients received chemotherapy only. Approximately 20% of TN and RR patient were treated with EGFR TKI only. Only 6.3% of TN patients received any immuno-oncologic therapy (IO) or combination, while this was higher in RR patients (29.6%). Overall, median OS was low at 16.2 months for TN patients, and 12.5 months for RR patients. Treatment with any IO was associated with poor survival in TN (6.1 months) and RR (8.0 months) patients.